Mutual Funds › MFIC › Sectoral/Thematic › Tata India Pharma & Healthcare Fund

Tata India Pharma & Healthcare Fund

Tata Mutual Fund · Sectoral/Thematic · Regular plan, growth option

NAV (₹), 2 Oct 2026
32.1622
1-day change
-0.64%
1Y return
6.4%
3Y CAGR
16.5%
5Y CAGR
12.3%
Max drawdown, 5Y
−17.7%
NAV history month-end NAV, ₹ · 29 Dec 2015 to 1 Oct 2026
8.021.033.9201620182020202220242026
Returns vs Sectoral/Thematic median (259 schemes) and “Healthcare & pharma” median (19)
PeriodSchemeCategory medianHealthcare & pharma median
1 month-4.4%-5.4%-3.2%
3 months-0.5%-3.1%2.7%
6 months14.4%8.5%21.0%
Year to date6.5%-2.6%16.3%
1 year6.4%0.0%16.0%
3 years (CAGR)16.5%11.7%19.2%
5 years (CAGR)12.3%10.6%13.7%
7 years (CAGR)20.5%15.7%23.7%
10 years (CAGR)12.9%13.3%13.4%
Since first NAV (CAGR)11.4%––

“Healthcare & pharma” is MFIC's grouping of Sectoral/Thematic schemes by the theme or index in their names, not an AMFI category.

Rolling returns every business-day start date
MeasureSchemeCategory median
1Y rolling median7.3%9.8%
3Y rolling median19.4%15.6%
3Y rolling worst-5.1%0.6%
3Y periods positive88%100%
3Y periods ahead of benchmark68%71%
5Y rolling median14.9%14.2%
5Y rolling worst7.5%0.3%
5Y periods ahead of benchmark58%70%

Benchmark: Nifty 500 (proxy: Motilal Oswal Nifty 500 Index Fund, price return).

Risk 36 months, monthly returns, Rf 6.5%
MeasureSchemeCategory median
Standard deviation (ann.)16.5%16.7%
Sharpe ratio0.700.34
Sortino ratio1.140.51
Beta0.790.96
Alpha (ann.)8.8%2.3%
Upside capture107.68103.56
Downside capture69.8896.87
Drawdowns peak-to-trough falls in NAV
MeasureSchemeCategory median
Maximum drawdown, full history−21.9%−23.7%
Maximum drawdown, last 10Y−18.6%−39.3%
Maximum drawdown, last 5Y−17.7%−22.8%
Current drawdown−5.4%−8.8%
Recovery time of worst fall624 days–

Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.

Cost, size and riskometer as disclosed to AMFI
MeasureSchemeCategory median
Expense ratio (TER), Regular plann/a2.65%
AUM, whole scheme (₹ crore)n/a1,245
Riskometern/a–

TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.

Official benchmark and category consistency
MeasureSchemeBenchmark / category
Month-ends above category median (3Y CAGR)67%53% median
Month-ends in category top quartile (3Y)45%24% median
7Y rolling CAGR, median (monthly windows)18.4%13.5% median

Category consistency: last 10 years of month-ends, Sectoral/Thematic Regular plans; how it is calculated.

Calendar-year returns NAV change from 31 Dec to 31 Dec
YearSchemeNifty 500 proxyDifference
2026 YTD6.5%-7.8%+14.2%
2025-4.9%7.7%−12.6%
202440.4%15.6%+24.8%
202336.6%26.5%+10.0%
2022-8.0%3.8%−11.8%
202119.1%30.6%−11.6%
202064.4%17.2%+47.1%
20195.5%n/a–
2018-2.6%n/a–
20174.7%n/a–

Benchmark proxy: Motilal Oswal Nifty 500 Index Fund (Direct plan NAV, price return), which carries its own costs. The first year starts from the first 31 December in the scheme's history.

Monthly SIP of ₹10,000 first business day of each month, ending 2 Oct 2026
PeriodInvestedValueXIRR
1 year₹1,20,000₹1,25,4688.5%
3 years₹3,60,000₹4,14,6779.4%
5 years₹6,00,000₹8,70,11714.8%
10 years₹12,00,000₹28,16,92816.3%

Uses this plan's NAVs; ignores stamp duty, exit loads and taxes. One historical path only — the interactive SIP analyzer shows outcomes across every start date.

Scheme facts
AMC: Tata Mutual Fund
Category: Sectoral/Thematic
Plan / option: Regular · Growth
AMFI scheme code: 135812
ISIN: INF277K016A9
First NAV in MFIC data: 29 Dec 2015
History: 10.8 years
Expense ratio, AUM, portfolio: see the scheme's factsheet
Schemes that behaved similarly correlation of monthly returns, last 5 years
SchemeCategoryCorrelation3Y CAGR
Mirae Asset Healthcare FundSectoral/Thematic0.9820.0%
Aditya Birla Sun Life Pharma and Healthcare FundSectoral/Thematic0.9718.5%
Nippon India Pharma FundSectoral/Thematic0.9716.6%
ICICI Prudential Healthcare FundSectoral/Thematic0.9720.1%
UTI - Healthcare FundSectoral/Thematic0.9721.4%
ITI Pharma and Healthcare FundSectoral/Thematic0.9716.7%
Questions about Tata India Pharma & Healthcare Fund
What is the latest NAV of Tata India Pharma & Healthcare Fund?
The NAV of the Regular plan (growth option) was ₹32.1622 on 2 Oct 2026, as published by AMFI.
Which category is Tata India Pharma & Healthcare Fund in?
It is classified as Sectoral/Thematic in AMFI's daily NAV file; a Sectoral/Thematic scheme invests at least 80% in one sector or theme. MFIC compares it with 259 Sectoral/Thematic schemes (Regular plans).
What returns has Tata India Pharma & Healthcare Fund delivered?
Over one year the NAV changed by 6.4%. The 3-year CAGR is 16.5% (category median 11.7%) and the 5-year CAGR is 12.3% (category median 10.6%). Returns are after expenses and before tax. Past performance may or may not be sustained in future.
How consistent have its 3-year returns been?
Measuring a 3-year CAGR from every business day in its history, the median was 19.4%, the lowest was -5.1%, and 88% of 3-year periods ended with a gain. It was ahead of Nifty 500 (index-fund proxy) in 68% of those periods.
What was the largest fall in Tata India Pharma & Healthcare Fund's NAV?
The largest peak-to-trough fall in its available history was 21.9%; within the last five years it was 17.7% (category median 22.8%).
How volatile is Tata India Pharma & Healthcare Fund?
Its annualised standard deviation of monthly returns over the last 36 months is 16.5%, which is below the Sectoral/Thematic category median of 16.7%.
What would a monthly SIP in Tata India Pharma & Healthcare Fund have grown to?
A SIP of ₹10,000 on the first business day of each month for the last 5 years (60 instalments, ₹6,00,000 invested) would have been worth about ₹8,70,117 on 2 Oct 2026, an annualised return (XIRR) of 14.8%. This uses the Regular plan's NAVs, ignores taxes and exit loads, and past performance may or may not be sustained in future.
How often has Tata India Pharma & Healthcare Fund beaten its category?
At 67% of the 94 month-ends compared over the last 10 years, its 3-year return was above the median of Sectoral/Thematic schemes (Regular plans); it was in the top quarter at 45% of them. A typical scheme would show about 50%.
What is the difference between the Direct and Regular plans?
Both plans hold the same portfolio; the Regular plan includes distribution costs in its expense ratio. Over one year the Direct plan's NAV changed by 7.9% and the Regular plan's by 6.4%. The Regular plan includes the services of a distributor.
Reviewing your own mutual fund portfolio?
Integrato's team can walk you through how your current schemes have behaved, using the same data shown here. Integrato is an AMFI-registered Mutual Fund Distributor.
Follow Tata India Pharma & Healthcare Fund by email

Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.

We email a confirmation link first. Integrato is an AMFI-registered Mutual Fund Distributor (ARN-173155); these emails are information, not recommendations.

Data & disclosure. Source: AMFI daily NAV file and historical NAVs via mfapi.in; calculations by MFIC, as of 2 Oct 2026. Category medians use Regular plans in the same AMFI category. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance may or may not be sustained in future. This page is for research and education only and is not investment advice or a recommendation to buy, sell or hold any scheme. Integrato Financial Services Pvt. Ltd. is an AMFI-registered Mutual Fund Distributor (ARN-173155). Methodology.